Recent advances in molecular biomarkers for patients with hepatocellular carcinoma

References

• Allemani C, Weir HK, Carreira H, et al. Global surveillance of cancer survival 1995-2009: analysis of individual data for 25,676,887 patients from 279 population-based registries in 67 countries (CONCORD-2). Lancet. 2015;385(9972):977–1010.
   PubMed Web of Science ®Google Scholar
• Kanda M, Murotani K, Sugimoto H, et al. An integrated multigene expression panel to predict long-term survival after curative hepatectomy in patients with hepatocellular carcinoma. Oncotarget. 2017;8(41):71070–71079.
   PubMedGoogle Scholar
• Mokdad AA, Hester CA, Singal AG, et al. Management of hepatocellular in the United States. Chin Clin Oncol. 2017;6(2):21.
   PubMed Web of Science ®Google Scholar
• Shimizu D, Kanda M, Sugimoto H, et al. The protein arginine methyltransferase 5 promotes malignant phenotype of hepatocellular carcinoma cells and is associated with adverse patient outcomes after curative hepatectomy. Int J Oncol. 2017;50(2):381–386.
   PubMed Web of Science ®Google Scholar
• Ezaka K, Kanda M, Sugimoto H, et al. Reduced expression of adherens junctions associated Protein 1 predicts recurrence of hepatocellular carcinoma after curative hepatectomy. Ann Surg Oncol. 2015;22(Suppl 3):S1499–1507. ** This study demonstrated that AJAP1 expressions were suppressed in HCC tissues and low levels of AJAP1 mRNA in patients was associated with malignant phenotype, hypermethylation of AJAP1 promotor, and copy number loss and poor prognosis.
   PubMedGoogle Scholar
• Best J, Bilgi H, Heider D, et al. The GALAD scoring algorithm based on AFP, AFP-L3, and DCP significantly improves detection of BCLC early stage hepatocellular carcinoma. Z Gastroenterol. 2016;54(12):1296–1305.
   PubMed Web of Science ®Google Scholar
• Shimizu D, Kanda M, Sugimoto H, et al. NRAGE promotes the malignant phenotype of hepatocellular carcinoma. Oncol Lett. 2016;11(3):1847–1854.
   PubMed Web of Science ®Google Scholar
• Ghouri YA, Mian I, Rowe JH. Review of hepatocellular carcinoma: epidemiology, etiology, and carcinogenesis. J Carcinog. 2017;16:1.
   PubMedGoogle Scholar
• Umeda S, Kanda M, Kodera Y. Emerging evidence of molecular biomarkers in hepatocellular carcinoma. Histol Histopathol. 2018;33(4):343–355. ** This article reviewed HCC related molecular biomarkers including oncogene, tumor suppressor gene, micro RNA and long non-coding RNA between Janualy 2015 and December 2016.
   PubMed Web of Science ®Google Scholar
• Kanda M, Sugimoto H, Kodera Y. Genetic and epigenetic aspects of initiation and progression of hepatocellular carcinoma. World J Gastroenterol. 2015;21(37):10584–10597.
   PubMed Web of Science ®Google Scholar
• Kanda M, Kodera Y. Molecular mechanisms of peritoneal dissemination in gastric cancer. World J Gastroenterol. 2016;22(30):6829–6840.
   PubMed Web of Science ®Google Scholar
• Umeda S, Kanda M, Miwa T, et al. Expression of sushi domain containing two reflects the malignant potential of gastric cancer. Cancer Med. 2018;7(10):5194–5204.
   PubMed Web of Science ®Google Scholar
• Shimizu D, Kanda M, Kodera Y. Emerging evidence of the molecular landscape specific for hematogenous metastasis from gastric cancer. World J Gastrointest Oncol. 2018;10(6):124–136.
   PubMed Web of Science ®Google Scholar
• Liu Z, Li J, Chen J, et al. MCM family in HCC: MCM6 indicates adverse tumor features and poor outcomes and promotes S/G2 cell cycle progression. BMC Cancer. 2018;18(1):200.
   PubMedGoogle Scholar
• Liu M, Hu Q, Tu M, et al. MCM6 promotes metastasis of hepatocellular carcinoma via MEK/ERK pathway and serves as a novel serum biomarker for early recurrence. J Exp Clin Cancer Res. 2018;37(1):10.
   PubMedGoogle Scholar
• Liu CQ, Xu J, Zhou ZG, et al. Expression patterns of programmed death ligand 1 correlate with different microenvironments and patient prognosis in hepatocellular carcinoma. Br J Cancer. 2018;119(1):80–88.
   PubMed Web of Science ®Google Scholar
• Wang R, Yu Z, Chen F, et al. Overexpression of ARID4B predicts poor survival in patients with hepatocellular carcinoma. Hum Pathol. 2018;73:114–121.
   PubMed Web of Science ®Google Scholar
• Jiang Z, Zhai X, Shi B, et al. KIAA1199 overexpression is associated with abnormal expression of EMT markers and is a novel independent prognostic biomarker for hepatocellular carcinoma. Onco Targets Ther. 2018;11:8341–8348.
   PubMed Web of Science ®Google Scholar
• Tang J, Ou J, Xu C, et al. EVI5 is a novel independent prognostic predictor in hepatocellular carcinoma after radical hepatectomy. Oncol Rep. 2017;38(4):2251–2258.
   PubMed Web of Science ®Google Scholar
• Fu X, Zhu Y, Zheng B, et al. KIFC1, a novel potential prognostic factor and therapeutic target in hepatocellular carcinoma. Int J Oncol. 2018;52(6):1912–1922.
   PubMed Web of Science ®Google Scholar
• Wang H, Kohashi K, Yoshizumi T, et al. Coexpression of SALL4 with HDAC1 and/or HDAC2 is associated with underexpression of PTEN and poor prognosis in patients with hepatocellular carcinoma. Hum Pathol. 2017;64:69–75.
   PubMed Web of Science ®Google Scholar
• Jiang L, Yan Q, Fang S, et al. Calcium-binding protein 39 promotes hepatocellular carcinoma growth and metastasis by activating extracellular signal-regulated kinase signaling pathway. Hepatology. 2017;66(5):1529–1545.
   PubMed Web of Science ®Google Scholar
• Huang D, Cao L, Zheng S. CAPZA1 modulates EMT by regulating actin cytoskeleton remodelling in hepatocellular carcinoma. J Exp Clin Cancer Res. 2017;36(1):13.
   PubMedGoogle Scholar
• Liu WB, Jia WD, Ma JL, et al. Knockdown of GTPBP4 inhibits cell growth and survival in human hepatocellular carcinoma and its prognostic significance. Oncotarget. 2017;8(55):93984–93997.
   PubMedGoogle Scholar
• Meng J, Liu Y, Han J, et al. Hsp90beta promoted endothelial cell-dependent tumor angiogenesis in hepatocellular carcinoma. Mol Cancer. 2017;16(1):72.
   PubMedGoogle Scholar
• Wan J, Liu H, Yang L, et al. JMJD6 promotes hepatocellular carcinoma carcinogenesis by targeting CDK4. Int J Cancer. 2019;144(10):2489–2500.
   PubMed Web of Science ®Google Scholar
• Wang M, Zhao X, Zhu D, et al. HIF-1alpha promoted vasculogenic mimicry formation in hepatocellular carcinoma through LOXL2 up-regulation in hypoxic tumor microenvironment. J Exp Clin Cancer Res. 2017;36(1):60.
   PubMed Web of Science ®Google Scholar
• Zuo SR, Zuo XC, He Y, et al. Positive Expression of SMYD2 is associated with poor prognosis in patients with primary hepatocellular carcinoma. J Cancer. 2018;9(2):321–330.
   PubMed Web of Science ®Google Scholar
• Liu H, Hu J, Wei R, et al. SPAG5 promotes hepatocellular carcinoma progression by downregulating SCARA5 through modifying beta-catenin degradation. J Exp Clin Cancer Res. 2018;37(1):229.
   PubMedGoogle Scholar
• Xu J, Liang J, Meng YM, et al. Vascular CXCR4 Expression Promotes Vessel Sprouting and Sensitivity to Sorafenib Treatment in Hepatocellular Carcinoma. Clin Cancer Res. 2017;23(15):4482–4492. * This study revealed that CXCR4 was expressed only in tumor vasculature and that patients with high CXCR4 vascular density were associated with poor prognosis. Moreover, CXCR4 expression was associated with sorafenib effectiveness in vivo orthotopic model and in HCC patients.
   PubMed Web of Science ®Google Scholar
• Qin XY, Suzuki H, Honda M, et al. Prevention of hepatocellular carcinoma by targeting MYCN-positive liver cancer stem cells with acyclic retinoid. Proc Natl Acad Sci U S A. 2018;115(19):4969–4974.
   PubMed Web of Science ®Google Scholar
• Kleylein-Sohn J, Pollinger B, Ohmer M, et al. Acentrosomal spindle organization renders cancer cells dependent on the kinesin HSET. J Cell Sci. 2012;125(Pt 22):5391–5402.
   PubMed Web of Science ®Google Scholar
• Karos M, Fischer R. Molecular characterization of HymA, an evolutionarily highly conserved and highly expressed protein of Aspergillus nidulans. Mol Gen Genet. 1999;260(6):510–521.
   PubMedGoogle Scholar
• Filippi BM, de Los Heros P, Mehellou Y, et al. MO25 is a master regulator of SPAK/OSR1 and MST3/MST4/YSK1 protein kinases. Embo J. 2011;30(9):1730–1741.
   PubMed Web of Science ®Google Scholar
• Kagan HM, Trackman PC. Properties and function of lysyl oxidase. Am J Respir Cell Mol Biol. 1991;5(3):206–210.
   PubMed Web of Science ®Google Scholar
• Zhuo W, Jia L, Song N, et al. The CXCL12-CXCR4 chemokine pathway: a novel axis regulates lymphangiogenesis. Clin Cancer Res. 2012;18(19):5387–5398.
   PubMed Web of Science ®Google Scholar
• Liu Y, Song L, Ni H, et al. ERBB4 acts as a suppressor in the development of hepatocellular carcinoma. Carcinogenesis. 2017;38(4):465–473.
   PubMed Web of Science ®Google Scholar
• Friedmann T. Gene therapy of cancer through restoration of tumor-suppressor functions? Cancer. 1992;70(6 Suppl):1810–1817.
   PubMed Web of Science ®Google Scholar
• Tanaka Y, Kanda M, Sugimoto H, et al. Translational implication of Kallmann syndrome-1 gene expression in hepatocellular carcinoma. Int J Oncol. 2015;46(6):2546–2554.
   PubMed Web of Science ®Google Scholar
• Umeda S, Kanda M, Koike M, et al. Copine 5 expression predicts prognosis following curative resection of esophageal squamous cell carcinoma. Oncol Rep. 2018;40(6):3772–3780.
   PubMed Web of Science ®Google Scholar
• Liu Y, Jiang P, Wang G, et al. Downregulation of RFX1 predicts poor prognosis of patients with small hepatocellular carcinoma. Eur J Surg Oncol. 2018;44(7):1087–1093.
   PubMed Web of Science ®Google Scholar
• Wang YY, Qi LN, Zhong JH, et al. High expression of AKR1B10 predicts low risk of early tumor recurrence in patients with hepatitis B virus-related hepatocellular carcinoma. Sci Rep. 2017;7:42199.
   PubMed Web of Science ®Google Scholar
• Yang Y, Zhang N, Zhu J, et al. Downregulated connexin32 promotes EMT through the Wnt/beta-catenin pathway by targeting Snail expression in hepatocellular carcinoma. Int J Oncol. 2017;50(6):1977–1988.
   PubMed Web of Science ®Google Scholar
• Umeda S, Kanda M, Sugimoto H, et al. Downregulation of GPR155 as a prognostic factor after curative resection of hepatocellular carcinoma. BMC Cancer. 2017;17(1):610. * This study found that downregulation of GPR155 was significantly associated with malignant phenotype of HCC and poor prognosis. Expression of GPR155 was significantly lower in patients who experienced extrahepatic recurrences. In addition, GPR155 predicted patient prognosis regardless of hepatitis infection.
   PubMedGoogle Scholar
• Li S, Han X, Lyu N, et al. Mechanism and prognostic value of indoleamine 2,3-dioxygenase 1 expressed in hepatocellular carcinoma. Cancer Sci. 2018;109(12):3726–3736.
   PubMed Web of Science ®Google Scholar
• Ji F, Zhang ZH, Zhang Y, et al. Low expression of c-Myc protein predicts poor outcomes in patients with hepatocellular carcinoma after resection. BMC Cancer. 2018;18(1):460.
   PubMedGoogle Scholar
• Fan M, Shen J, Liu H, et al. Downregulation of PRRX1 via the p53-dependent signaling pathway predicts poor prognosis in hepatocellular carcinoma. Oncol Rep. 2017;38(2):1083–1090.
   PubMed Web of Science ®Google Scholar
• Chen P, Lei L, Wang J, et al. Downregulation of Talin1 promotes hepatocellular carcinoma progression through activation of the ERK1/2 pathway. Cancer Sci. 2017;108(6):1157–1168. * This study revealed that downregulation of TLN1 was significantly correlated with younger age, larger tumor size, higher α-fetoprotein level and poor prognosis. TLN1 knockdown induced EMT by regulating E-cadherin, N-cadherin, vimentin and β-catenin. ERK1/2 was significantly elevated in TLN1 knockdown cells.
   PubMed Web of Science ®Google Scholar
• Ke Y, Bao T, Zhou Q, et al. Discs large homolog 5 decreases formation and function of invadopodia in human hepatocellular carcinoma via Girdin and Tks5. Int J Cancer. 2017;141(2):364–376.
   PubMed Web of Science ®Google Scholar
• Zhang S, Zhang K, Ji P, et al. GABPA predicts prognosis and inhibits metastasis of hepatocellular carcinoma. BMC Cancer. 2017;17(1):380.
   PubMedGoogle Scholar
• Lui KY, Zhao H, Qiu C, et al. Integrator complex subunit 6 (INTS6) inhibits hepatocellular carcinoma growth by Wnt pathway and serve as a prognostic marker. BMC Cancer. 2017;17(1):644.
   PubMedGoogle Scholar
• Cheng Y, Xing SG, Jia WD, et al. Low PLCE1 levels are correlated with poor prognosis in hepatocellular carcinoma. Onco Targets Ther. 2017;10:47–54.
   PubMed Web of Science ®Google Scholar
• Shao X, Lu Q, Wang G, et al. Reduced expression of Nrdp1 predicts a poor prognosis in human hepatocellular carcinoma. Onco Targets Ther. 2018;11:4955–4963.
   PubMed Web of Science ®Google Scholar
• Yang Y, Zhou Y, Hou J, et al. Hepatic IFIT3 predicts interferon-alpha therapeutic response in patients of hepatocellular carcinoma. Hepatology. 2017;66(1):152–166.
   PubMed Web of Science ®Google Scholar
• Komatsu H, Iguchi T, Masuda T, et al. Attenuated RND1 expression confers malignant phenotype and predicts poor prognosis in hepatocellular carcinoma. Ann Surg Oncol. 2017;24(3):850–859.
   PubMed Web of Science ®Google Scholar
• Feng C, Zuo Z. Regulatory factor X1-induced down-regulation of transforming growth factor beta2 transcription in human neuroblastoma cells. J Biol Chem. 2012;287(27):22730–22739.
   PubMed Web of Science ®Google Scholar
• Aftab S, Semenec L, Chu JS, et al. Identification and characterization of novel human tissue-specific RFX transcription factors. BMC Evol Biol. 2008;8:226.
   PubMed Web of Science ®Google Scholar
• Calderwood DA, Ginsberg MH. Talin forges the links between integrins and actin. Nat Cell Biol. 2003;5(8):694–697.
   PubMed Web of Science ®Google Scholar
• Trifonov S, Houtani T, Shimizu J, et al. GPR155: gene organization, multiple mRNA splice variants and expression in mouse central nervous system. Biochem Biophys Res Commun. 2010;398(1):19–25.
   PubMed Web of Science ®Google Scholar
• Shimizu D, Kanda M, Tanaka H, et al. GPR155 serves as a predictive biomarker for hematogenous metastasis in patients with gastric cancer. Sci Rep. 2017;7:42089.
   PubMed Web of Science ®Google Scholar
• Sun HC, Tang ZY, Wang L, et al. Postoperative interferon alpha treatment postponed recurrence and improved overall survival in patients after curative resection of HBV-related hepatocellular carcinoma: a randomized clinical trial. J Cancer Res Clin Oncol. 2006;132(7):458–465.
   PubMed Web of Science ®Google Scholar
• Shen YC, Hsu C, Chen LT, et al. Adjuvant interferon therapy after curative therapy for hepatocellular carcinoma (HCC): a meta-regression approach. J Hepatol. 2010;52(6):889–894.
   PubMed Web of Science ®Google Scholar
• Sawaki K, Kanda M, Kodera Y. Review of recent efforts to discover biomarkers for early detection, monitoring, prognosis, and prediction of treatment responses of patients with gastric cancer. Expert Rev Gastroenterol Hepatol. 2018;12(7):657–670.
   PubMed Web of Science ®Google Scholar
• Liu Y, Zhang X, Yang B, et al. Demethylation-induced overexpression of Shc3 Drives C-Raf-Independent Activation of MEK/ERK in HCC. Cancer Res. 2018;78(9):2219–2232. * This study revealed  correlation of SHC3 expression with microvascular invasion, cancer staging, and poor prognosis. SHC3 knock-in and knock-out analysis of the HCC cell line showed that SHC3 activates MEK and ERK pathways and promotes EMT. It also found that SHC3 expression was regulated by promotor methylation.
   PubMed Web of Science ®Google Scholar
• Fan H, Cui Z, Zhang H, et al. DNA demethylation induces SALL4 gene re-expression in subgroups of hepatocellular carcinoma associated with Hepatitis B or C virus infection. Oncogene. 2017;36(17):2435–2445.
   PubMed Web of Science ®Google Scholar
• He J, Huang Y, Liu Z, et al. Hypomethylation of BORIS is a promising prognostic biomarker in hepatocellular carcinoma. Gene. 2017;629:29–34.
   PubMed Web of Science ®Google Scholar
• Fan X, Guo H, Dai B, et al. The association between methylation patterns of DNAH17 and clinicopathological factors in hepatocellular carcinoma. Cancer Med. 2019;8(1):337–350.
   PubMed Web of Science ®Google Scholar
• Anwar SL, Krech T, Hasemeier B, et al. hsa-mir-183 is frequently methylated and related to poor survival in human hepatocellular carcinoma. World J Gastroenterol. 2017;23(9):1568–1575.
   PubMed Web of Science ®Google Scholar
• Ng PKS, Lau CPY, Lam EKY, et al. Hypermethylation of NF-kappaB-Activating Protein-Like (NKAPL) promoter in hepatocellular carcinoma suppresses its expression and predicts a poor prognosis. Dig Dis Sci. 2018;63(3):676–686.
   PubMed Web of Science ®Google Scholar
• Oikawa T, Kamiya A, Kakinuma S, et al. Sall4 regulates cell fate decision in fetal hepatic stem/progenitor cells. Gastroenterology. 2009;136(3):1000–1011.
   PubMed Web of Science ®Google Scholar
• Yong KJ, Gao C, Lim JS, et al. Oncofetal gene SALL4 in aggressive hepatocellular carcinoma. N Engl J Med. 2013;368(24):2266–2276.
   PubMed Web of Science ®Google Scholar
• Loukinov DI, Pugacheva E, Vatolin S, et al. BORIS, a novel male germ-line-specific protein associated with epigenetic reprogramming events, shares the same 11-zinc-finger domain with CTCF, the insulator protein involved in reading imprinting marks in the soma. Proc Natl Acad Sci U S A. 2002;99(10):6806–6811.
   PubMed Web of Science ®Google Scholar
• Xu Q, Liu X, Liu Z, et al. MicroRNA-1296 inhibits metastasis and epithelial-mesenchymal transition of hepatocellular carcinoma by targeting SRPK1-mediated PI3K/AKT pathway. Mol Cancer. 2017;16(1):103.
   PubMedGoogle Scholar
• Kanda M, Kodera Y. Recent advances in the molecular diagnostics of gastric cancer. World J Gastroenterol. 2015;21(34):9838–9852.
   PubMed Web of Science ®Google Scholar
• Rupaimoole R, Slack FJ. MicroRNA therapeutics: towards a new era for the management of cancer and other diseases. Nat Rev Drug Discov. 2017;16(3):203–222.
   PubMed Web of Science ®Google Scholar
• Guo X, Lv X, Lv X, et al. Circulating miR-21 serves as a serum biomarker for hepatocellular carcinoma and correlated with distant metastasis. Oncotarget. 2017;8(27):44050–44058.
   PubMedGoogle Scholar
• Mansoori B, Mohammadi A, Shirjang S, et al. MicroRNAs in the diagnosis and treatment of cancer. Immunol Invest. 2017;46(8):880–897.
   PubMed Web of Science ®Google Scholar
• Shi M, Jiang Y, Yang L, et al. Decreased levels of serum exosomal miR-638 predict poor prognosis in hepatocellular carcinoma. J Cell Biochem. 2018;119(6):4711–4716.
   PubMed Web of Science ®Google Scholar
• Qu Z, Wu J, Wu J, et al. Exosomal miR-665 as a novel minimally invasive biomarker for hepatocellular carcinoma diagnosis and prognosis. Oncotarget. 2017;8(46):80666–80678.
   PubMedGoogle Scholar
• Jones KR, Nabinger SC, Lee S, et al. Lower expression of tumor microRNA-26a is associated with higher recurrence in patients with hepatocellular carcinoma undergoing surgical treatment. J Surg Oncol. 2018;118(3):431–439.
   PubMed Web of Science ®Google Scholar
• Jin Y, Wang J, Han J, et al. MiR-122 inhibits epithelial-mesenchymal transition in hepatocellular carcinoma by targeting Snail1 and Snail2 and suppressing WNT/beta-cadherin signaling pathway. Exp Cell Res. 2017;360(2):210–217.
   PubMed Web of Science ®Google Scholar
• Yu S, Jing L, Yin XR, et al. MiR-195 suppresses the metastasis and epithelial-mesenchymal transition of hepatocellular carcinoma by inhibiting YAP. Oncotarget. 2017;8(59):99757–99771.
   PubMedGoogle Scholar
• Yu Z, Lin X, Tian M, et al. microRNA196b promotes cell migration and invasion by targeting FOXP2 in hepatocellular carcinoma. Oncol Rep. 2018;39(2):731–738.
   PubMed Web of Science ®Google Scholar
• Ni JS, Zheng H, Huang ZP, et al. MicroRNA-197-3p acts as a prognostic marker and inhibits cell invasion in hepatocellular carcinoma. Oncol Lett. 2019;17(2):2317–2327.
   PubMed Web of Science ®Google Scholar
• Zhang H, Liu H, Bi H. MicroRNA-345 inhibits hepatocellular carcinoma metastasis by inhibiting YAP1. Oncol Rep. 2017;38(2):843–849.
   PubMed Web of Science ®Google Scholar
• Li P, Fan H, He Q. Investigation of the clinical significance and prognostic value of microRNA-145 in human hepatocellular carcinoma. Medicine (Baltimore). 2018;97(51):e13715.
   PubMed Web of Science ®Google Scholar
• Wang X, Lu J, Cao J, et al. MicroRNA-18a promotes hepatocellular carcinoma proliferation, migration, and invasion by targeting Bcl2L10. Onco Targets Ther. 2018;11:7919–7934.
   PubMed Web of Science ®Google Scholar
• Ye Y, Song Y, Zhuang J, et al. MicroRNA-302a-3p suppresses hepatocellular carcinoma progression by inhibiting proliferation and invasion. Onco Targets Ther. 2018;11:8175–8184.
   PubMed Web of Science ®Google Scholar
• Fang F, Song T, Zhang T, et al. MiR-425-5p promotes invasion and metastasis of hepatocellular carcinoma cells through SCAI-mediated dysregulation of multiple signaling pathways. Oncotarget. 2017;8(19):31745–31757. * This study demonstrated that high MIR425-5p expression is associated with tumor invasion and worse prognosis. MIR425 promoted HCC cell EMT, invasion and metastasis via SCAI-mediated dysregulation of integrin-β1-Fak/Src-Rho/CDC42, PTEN-AKT, and TIMP2-MMP2/MMP9 signaling.
   PubMedGoogle Scholar
• Chen X, Zhang Q, Ma W, et al. The Abnormal Expression of MicroRNA-542-3p in hepatocellular carcinoma and its clinical significance. Dis Markers. 2018;2018:3973250.
   PubMedGoogle Scholar
• Liu X, Yang L, Tu J, et al. microRNA-526b servers as a prognostic factor and exhibits tumor suppressive property by targeting Sirtuin 7 in hepatocellular carcinoma. Oncotarget. 2017;8(50):87737–87749.
   PubMedGoogle Scholar
• Kim SS, Nam JS, Cho HJ, et al. Plasma micoRNA-122 as a predictive marker for treatment response following transarterial chemoembolization in patients with hepatocellular carcinoma. J Gastroenterol Hepatol. 2017;32(1):199–207.
   PubMed Web of Science ®Google Scholar
• Hu XY, Li L, Wu HT, et al. Serum miR-130b level, an ideal marker for monitoring the recurrence and prognosis of primary hepatocellular carcinoma after radiofrequency ablation treatment. Pathol Res Pract. 2018;214(10):1655–1660.
   PubMed Web of Science ®Google Scholar
• Sun L, Jiang R, Li J, et al. MicoRNA-425-5p is a potential prognostic biomarker for cervical cancer. Ann Clin Biochem. 2017;54(1):127–133.
   PubMed Web of Science ®Google Scholar
• Wang SC, Lin XL, Li J, et al. MicroRNA-122 triggers mesenchymal-epithelial transition and suppresses hepatocellular carcinoma cell motility and invasion by targeting RhoA. PLoS One. 2014;9(7):e101330.
   PubMed Web of Science ®Google Scholar
• Li Y, Ye Y, Feng B, et al. Long Noncoding RNA lncARSR promotes doxorubicin resistance in hepatocellular carcinoma via modulating PTEN-PI3K/Akt Pathway. J Cell Biochem. 2017;118(12):4498–4507.
   PubMed Web of Science ®Google Scholar
• Cao C, Zhang T, Zhang D, et al. The long non-coding RNA, SNHG6-003, functions as a competing endogenous RNA to promote the progression of hepatocellular carcinoma. Oncogene. 2017;36(8):1112–1122.
   PubMed Web of Science ®Google Scholar
• Bhan A, Soleimani M, Mandal SS. Long noncoding RNA and cancer: a new paradigm. Cancer Res. 2017;77(15):3965–3981.
   PubMed Web of Science ®Google Scholar
• Wang ZF, Hu R, Pang JM, et al. Serum long noncoding RNA LRB1 as a potential biomarker for predicting the diagnosis and prognosis of human hepatocellular carcinoma. Oncol Lett. 2018;16(2):1593–1601.
   PubMed Web of Science ®Google Scholar
• Toraih EA, Ellawindy A, Fala SY, et al. Oncogenic long noncoding RNA MALAT1 and HCV-related hepatocellular carcinoma. Biomed Pharmacother. 2018;102:653–669.
   PubMed Web of Science ®Google Scholar
• Cao SW, Huang JL, Chen J, et al. Long non-coding RNA UBE2CP3 promotes tumor metastasis by inducing epithelial-mesenchymal transition in hepatocellular carcinoma. Oncotarget. 2017;8(39):65370–65385. * Transcriptome analysis found that UBE2CP3 was upregulated in HCC. Tissue and serum UBE2CP3 expression levels were upregulated in HCC and that high UBE2CP3 correlated with poor prognosis. Overexpression of UBE2CP3 promoted cell invasion and migration. Enhanced expression of UBE2CP3 promoted EMT by increasing the expression of Snail and N-cadherin.
   PubMedGoogle Scholar
• Jang SY, Kim G, Park SY, et al. Clinical significance of lncRNA-ATB expression in human hepatocellular carcinoma. Oncotarget. 2017;8(45):78588–78597.
   PubMedGoogle Scholar
• Cheng S, Li T, Wang C, et al. Decreased long intergenic noncoding RNA P7 predicts unfavorable prognosis and promotes tumor proliferation via the modulation of the STAT1-MAPK pathway in hepatocellular carcinoma. Oncotarget. 2018;9(90):36057–36066.
   PubMedGoogle Scholar
• Zhang J, Zhang D, Zhao Q, et al. A distinctively expressed long noncoding RNA, RP11-466I1.1, may serve as a prognostic biomarker in hepatocellular carcinoma. Cancer Med. 2018;7(7):2960-2968.
   Web of Science ®Google Scholar
• Lan T, Ma W, Hong Z, et al. Long non-coding RNA small nucleolar RNA host gene 12 (SNHG12) promotes tumorigenesis and metastasis by targeting miR-199a/b-5p in hepatocellular carcinoma. J Exp Clin Cancer Res. 2017;36(1):11.
   PubMedGoogle Scholar
• Sun J, Wei X, Xu L. Upregulation of lncRNA Sox2ot indicates a poor prognosis for patients with hepatocellular carcinoma and promotes cell invasion. Oncol Lett. 2018;16(1):1189–1195.
   PubMed Web of Science ®Google Scholar
• He T, Zhang L, Kong Y, et al. Long non-coding RNA CASC15 is upregulated in hepatocellular carcinoma and facilitates hepatocarcinogenesis. Int J Oncol. 2017;51(6):1722–1730.
   PubMed Web of Science ®Google Scholar
• Dou C, Sun L, Jin X, et al. Long non-coding RNA CARLo-5 promotes tumor progression in hepatocellular carcinoma via suppressing miR-200b expression. Oncotarget. 2017;8(41):70172–70182.
   PubMedGoogle Scholar
• Xu Y, Wang B, Zhang F, et al. Long non-coding RNA CCAT2 is associated with poor prognosis in hepatocellular carcinoma and promotes tumor metastasis by regulating Snail2-mediated epithelial-mesenchymal transition. Onco Targets Ther. 2017;10:1191–1198.
   PubMed Web of Science ®Google Scholar
• Yin L, Chen Y, Zhou Y, et al. Increased long noncoding RNA LASP1-AS is critical for hepatocellular carcinoma tumorigenesis via upregulating LASP1. J Cell Physiol. 2019.
   Web of Science ®Google Scholar
• Zhang LG, Zhou XK, Zhou RJ, et al. Long non-coding RNA LINC00673 promotes hepatocellular carcinoma progression and metastasis through negatively regulating miR-205. Am J Cancer Res. 2017;7(12):2536–2544.
   PubMed Web of Science ®Google Scholar
• Xu JH, Chang WH, Fu HW, et al. Upregulated long non-coding RNA LOC90784 promotes cell proliferation and invasion and is associated with poor clinical features in HCC. Biochem Biophys Res Commun. 2017;490(3):920–926.
   PubMed Web of Science ®Google Scholar
• ZA L, DD X, RM M, et al. LncRNA NEAT1 promotes deterioration of hepatocellular carcinoma based on in vitro experiments, data mining, and RT-qPCR analysis. Cell Physiol Biochem. 2018;48(2):540–555.
   PubMedGoogle Scholar
• Li Y, Liu G, Li X, et al. Long non-coding RNA SBF2-AS1 promotes hepatocellular carcinoma progression through regulation of miR-140-5p-TGFBR1 pathway. Biochem Biophys Res Commun. 2018;503(4):2826–2832.
   PubMed Web of Science ®Google Scholar
• Qu L, Wu Z, Li Y, et al. A feed-forward loop between lncARSR and YAP activity promotes expansion of renal tumour-initiating cells. Nat Commun. 2016;7:12692.
   PubMed Web of Science ®Google Scholar
• Zender L, Villanueva A, Tovar V, et al. Cancer gene discovery in hepatocellular carcinoma. J Hepatol. 2010;52(6):921–929.
   PubMed Web of Science ®Google Scholar
• Zhu YJ, Zheng B, Wang HY, et al. New knowledge of the mechanisms of sorafenib resistance in liver cancer. Acta Pharmacol Sin. 2017;38(5):614–622.
   PubMed Web of Science ®Google Scholar
• Hoshi T, Watanabe Miyano S, Watanabe H, et al. Lenvatinib induces death of human hepatocellular carcinoma cells harboring an activated FGF signaling pathway through inhibition of FGFR-MAPK cascades. Biochem Biophys Res Commun. 2019;513(1):1–7.
   PubMed Web of Science ®Google Scholar
• Barclay J, Creswell J, Leon J. Cancer immunotherapy and the PD-1/PD-L1 checkpoint pathway. Arch Esp Urol. 2018;71(4):393–399.
   PubMed Web of Science ®Google Scholar
• Bruix J, Qin S, Merle P, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;389(10064):56–66.
   PubMed Web of Science ®Google Scholar
• BP ML, Miksad RA. Cabozantinib in the treatment of hepatocellular carcinoma. Future Oncol. 2017;13(22).
   Web of Science ®Google Scholar
• Dey P, Rathod M, De A. Targeting stem cells in the realm of drug-resistant breast cancer. Breast Cancer (Dove Med Press). 2019;11:115–135.
   PubMed Web of Science ®Google Scholar
• Du B, Shim JS. Targeting Epithelial-Mesenchymal Transition (EMT) to overcome drug resistance in cancer. Molecules. 2016;21(7).
   Web of Science ®Google Scholar
• Shibata C, Ohno M, Otsuka M, et al. The flavonoid apigenin inhibits hepatitis C virus replication by decreasing mature microRNA122 levels. Virology. 2014;462-463:42–48.
   PubMed Web of Science ®Google Scholar
• Beg MS, Brenner AJ, Sachdev J, et al. Phase I study of MRX34, a liposomal miR-34a mimic, administered twice weekly in patients with advanced solid tumors. Invest New Drugs. 2017;35(2):180–188.
   PubMed Web of Science ®Google Scholar
• Valadi H, Ekstrom K, Bossios A, et al. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol. 2007;9(6):654–659.
   PubMed Web of Science ®Google Scholar
• Tang A, Bashir MR, Corwin MT, et al. Evidence Supporting LI-RADS Major Features for CT- and MR imaging-based diagnosis of hepatocellular carcinoma: a systematic review. Radiology. 2018;286(1):29–48.
   PubMed Web of Science ®Google Scholar
• Zhu AX, Kang YK, Yen CJ, et al. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased alpha-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019;20(2):282–296.
   PubMed Web of Science ®Google Scholar
• Calderaro J, Couchy G, Imbeaud S, et al. Histological subtypes of hepatocellular carcinoma are related to gene mutations and molecular tumour classification. J Hepatol. 2017;67(4):727–738.
   PubMed Web of Science ®Google Scholar